160 related articles for article (PubMed ID: 22795807)
1. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
[TBL] [Abstract][Full Text] [Related]
2. Effect of immunosuppressive drugs on DNA repair in human peripheral blood mononuclear cells.
Herman-Edelstein M; Rozen-Zvi B; Zingerman B; Lichtenberg S; Malachi T; Gafter U; Ori Y
Biomed Pharmacother; 2012 Mar; 66(2):111-5. PubMed ID: 22244961
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.
Lamoureux F; Picard N; Boussera B; Sauvage FL; Marquet P
Fundam Clin Pharmacol; 2012 Aug; 26(4):463-72. PubMed ID: 21631587
[TBL] [Abstract][Full Text] [Related]
4. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
Niemczyk M; Zegarska J; Pawłowska M; Wyzgał J; Ciszek M; Paczek L
Transpl Immunol; 2009 Jan; 20(3):139-42. PubMed ID: 18834941
[TBL] [Abstract][Full Text] [Related]
5. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.
van Rossum HH; Romijn FP; Smit NP; de Fijter JW; van Pelt J
Biochem Pharmacol; 2009 Apr; 77(7):1206-12. PubMed ID: 19154728
[TBL] [Abstract][Full Text] [Related]
6. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
[TBL] [Abstract][Full Text] [Related]
7. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J
J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression.
Thoms KM; Kuschal C; Oetjen E; Mori T; Kobayashi N; Laspe P; Boeckmann L; Schön MP; Emmert S
Exp Dermatol; 2011 Mar; 20(3):232-6. PubMed ID: 21323745
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U
J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.
Hoogduijn MJ; Crop MJ; Korevaar SS; Peeters AM; Eijken M; Maat LP; Balk AH; Weimar W; Baan CC
Transplantation; 2008 Nov; 86(9):1283-91. PubMed ID: 19005411
[TBL] [Abstract][Full Text] [Related]
12. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Patsenker E; Schneider V; Ledermann M; Saegesser H; Dorn C; Hellerbrand C; Stickel F
J Hepatol; 2011 Aug; 55(2):388-98. PubMed ID: 21168455
[TBL] [Abstract][Full Text] [Related]
13. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
[No Abstract] [Full Text] [Related]
14. DNA repair in mononuclear cells: role of serine/threonine phosphatases.
Herman M; Ori Y; Chagnac A; Weinstein T; Korzets A; Zevin D; Malachi T; Gafter U
J Lab Clin Med; 2002 Oct; 140(4):255-62. PubMed ID: 12389024
[TBL] [Abstract][Full Text] [Related]
15. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
16. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
17. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
18. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
19. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitors and rapamycin: cancer protection or promotion?
Weischer M; Röcken M; Berneburg M
Exp Dermatol; 2007 May; 16(5):385-93. PubMed ID: 17437481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
